CareRx Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHHHF research report →
Price Chart
About the company
CareRx Corporation, operating with its subsidiaries, specializes in delivering tailored pharmaceutical services to Canada's senior demographic. The company manages a vast network of medication dispensing facilities, which are responsible for providing chronic prescriptions and a variety of other advanced clinical pharmacy solutions. Currently, it caters to approximately 50,000 individuals residing in roughly 900 distinct senior and communal living environments, including extended care residences, retirement communities, supportive living facilities, and group homes.
- CEO
- Puneet Khanna
- IPO
- 2017
- Employees
- 1,533
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on CHHHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $140.44M
- P/E
- 7.79
- Fwd P/E
- 34.29
- PEG
- 0.00
- P/S
- 0.53
- P/B
- 1.86
- EV/EBITDA
- 9.44
- Div Yield
- 2.58%
- Gross Margin
- 26.18%
- Op Margin
- 3.27%
- Net Margin
- 6.75%
- ROE
- 23.35%
- ROIC
- 6.55%
Latest fiscal year · YoY change
- Revenue
- $369.94M+0.9%
- Gross Profit
- $92.55M-14.3%
- Op Income
- $11.87M
- Net Income
- $26.11M+680.0%
- EPS
- $0.42+660.7%
- OCF Growth
- -27.6%
- FCF Growth
- -26.6%
- 52W High
- $2.89
- 52W Low
- $2.22
- 50D MA
- $2.34
- 200D MA
- $2.48
- Beta
- 0.60
- RSI (14)
- 24
- Avg Volume
- 8
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CareRx posted steady Q3 growth with higher bed count and revenue, while margin held at 8.5% despite Ontario ward-bed changes and onboarding costs.· November 5, 2026
- Revenue rose 2.2% year over year to $95.3 million, driven by higher average beds serviced.
- Adjusted EBITDA was $8.1 million with an 8.5% margin, versus $8.3 million and 9.0% a year ago.
- Average beds serviced increased to 93,225 from 91,298 in Q3 2025, helped by the new national operator adding about 3,000 beds.
- Net income was about $240,000, down from $1.6 million last year, mainly due to a noncash deferred tax expense and refinancing fees.
- Management highlighted strong cash generation, a new credit facility, share repurchases, and a quarterly dividend of $0.022 per share.
Q3 2026 revenue was $95.3 million, up 2.2% from $93.2 million in Q3 2025. Adjusted EBITDA was approximately $8.1 million versus $8.3 million a year ago, with adjusted EBITDA margin at 8.5% versus 9.0% last year. Net income was approximately $240,000, down from $1.6 million in Q3 2025, mainly because of a noncash deferred tax expense of about $450,000 and upfront refinancing fees. Average beds serviced increased to 93,225 from 91,298 in the prior-year quarter. Cash from operations was $6.5 million versus $10.1 million in Q3 2025, cash was $10.7 million at September 30, 2026, net debt was $29.6 million, and net debt to adjusted EBITDA was 0.9x. Management said Q4 should benefit from the full-quarter impact of the newly onboarded 3,000-bed contract, with no further onboarding-related one-time expenses expected to recur, though rising gas prices remain a headwind. They also said they continue to pursue new customer wins, accretive acquisitions, and efficiency gains through network optimization.
Puneet Khanna said the quarter showed CareRx can onboard large contracts quickly and operate at scale, pointing to the approximately 3,000-bed national operator win as proof of the platform’s strength. He framed the business as well positioned for demographic growth, more organic customer wins, and potential accretive acquisitions using the new credit capacity. His tone was confident and operationally focused, with emphasis on service quality, clinical expertise, resident safety, and capital discipline.
Suzanne Brand emphasized that the quarter benefited from higher bed service and ongoing cost savings, but margins were pressured by Ontario ward-bed changes and labor timing tied to rapid onboarding. She quantified the financing impact by noting that, excluding accretion, finance costs declined 15% year over year, and she outlined the new credit agreement as a 5-year facility with a $40 million term loan, up to $20 million revolving facility, and a $10 million acquisition/CapEx facility. She also cited strong liquidity and capital returns: cash of $10.7 million, net debt of $29.6 million, 0.9x leverage, 207,000 shares repurchased in Q3 for about $670,000, and dividends paid after quarter-end totaling $1.4 million.
Analysts focused on whether CareRx had more bed additions in the funnel, how the new contract affects margin trajectory, and whether the margin dip reflected one-time onboarding costs or mix changes. Management said Q4 should show the full benefit of the 3,000-bed onboard and that the onboarding-related one-time expenses should not recur, but they also cautioned that labor costs were not linear and that some expected wins may slip into the new year. They also said a Western Canada pharmacy closure was done to improve network efficiency, with more optimization possible over time, while rising gas prices were called out as a current cost pressure.
The call showed CareRx can land and quickly integrate a large national operator, adding about 3,000 beds and supporting revenue growth. Management also pointed to a strong balance sheet, lower borrowing costs, repurchases, and a dividend, suggesting it has flexibility to fund growth while returning capital.
Margins were lower year over year, and management tied part of that to Ontario ward-bed changes, labor timing, and higher gas prices, which could pressure Q4 as well. Some expected bed wins may slide into 2027, and management acknowledged that the business is lumpy and timing is not fully under its control.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.9%
- Shares Outstanding
- 63.26M
- Float Shares
- 56.23M
Our CHHHF coverage
Recent articles, reports, and earnings notes.
No research on CHHHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHHHF report →CareRx Corporation (CRRX:CA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
CareRx Reports Voting Results from Annual General Meeting of Shareholders
newsfilecorp.com · May 28
CareRx Announces Q2 2026 Dividend
newsfilecorp.com · May 6
CareRx Reports Results for The First Quarter of 2026
newsfilecorp.com · May 6
CareRx Corporation to Host First Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 at 8:30 a.m. ET
newsfilecorp.com · Apr 27
CareRx Welcomes Stability in Long-Term Care Pharmacy Funding in Ontario
newsfilecorp.com · Apr 16
CareRx Corporation Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
newsfilecorp.com · Apr 15
CareRx Corporation (CRRX:CA) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.